Drugs / C-CAR066
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04316624 | Sep 2019 → Feb 2023 | diffuse large B-cell lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 1 | NCT04036019 | Aug 2019 → Jun 2022 | lymphoma | Shanghai Tongji Hospital, Tongji University School of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-CAR066 | “C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy” PMID 39351902 ↗ Oct 2024 |
| Known as | CBM.CD20 CAR-T | “A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy” NCT04036019 ↗ |
| Modality | Cell therapy | “C-CAR066, an autologous fully human anti-CD20 specific CAR-T” PMID 39351902 ↗ Oct 2024 |
| Route | Intravenous | “Patients received a single intravenous infusion of C-CAR066 at a target dose of 2.0 × 106 or 3.0 × 106 CAR-T cells/kg” PMID 39351902 ↗ Oct 2024 |